ALMR Alamar Biosciences, Inc.

28.68USD-6.00%Mkt Cap: 1.99B USDP/E: —

Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a prote…

Insiders, last 90 daysNet sellers
Institutional holders20 on file

Key Statistics

Company
Market Cap1.99B USD
Enterprise Value1.94B USD
Revenue (TTM)114.05M USD
Gross Profit41.70M USD
Net Income (TTM)-29.82M USD
Revenue/Share2.99 USD
Last Price28.68 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees308
CountryUS
SectorHealthcare
IndustryMedical Devices
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-38.39
PEG—
EV/EBITDA-43.70
EV/Revenue16.97
P/S17.47
P/B6.56
EPS (TTM)-1.13 USD
EPS (Forward)-0.75 USD
52W Range
18.8447% of range39.61
52W High39.61 USD
52W Low18.84 USD
Profitability
Gross Margin56.20%
Oper. Margin-42.08%
EBITDA Margin-38.84%
Profit Margin-40.18%
ROE18.76%
ROA-21.30%
ROIC—
ROCE-26.95%
Growth
Revenue Growth68.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-53.61M USD
CapEx (TTM)6.38M USD
FCF Margin—
FCF Yield—
Net Debt-184.23M USD
Net Debt/EBITDA4.16
Net Debt/FCF—
Balance Sheet
Debt/Equity-0.26
Current Ratio9.49
Quick Ratio7.41
Book Value/Sh4.37 USD
Cash/Share3.26 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)37.00 USD
Upside (mean)+29.0%
Target Range34.00 USD – 45.00 USD
34.00+29.0% to mean45.00
# Analysts5
Ownership
Shares Out.69.48M
Float37.75M
Insiders22.21%
Institutions56.36%
Short Interest
Short Ratio2.9d
Short % Float5.23%
Short % Out.3.23%
Shares Short2.24M
Short (prev mo.)2.81M
Technical
SMA 5030.25 (-5.2%)
SMA 20027.15 (+5.6%)
Beta—
S&P 52W Chg12.08%
Avg Vol (30d)748.40K
Avg Vol (10d)788.18K
Technical Indicators
RSI (14)45.3
MACD0.0836
MACD Signal0.1600
MACD Hist.-0.0764
BB Upper34.38 USD
BB Middle30.57 USD
BB Lower26.75 USD
BB Width24.96%
ATR (14)2.553 USD
Vol Ratio (20d)0.45x

About Alamar Biosciences (NASDAQ: ALMR)

›

Alamar Biosciences (NASDAQ: ALMR) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 308 employees.

The shares were at 28.68 USD on 19 November 2026. Its 52-week range is 18.84 USD to 39.61 USD: the price is 27.6% below the high and 52.2% above the low.

Its market capitalisation is 1.99B USD.

Alamar Biosciences reports return on equity of 18.8%, an operating margin of -42.1% and revenue up 68.5% year over year.

It holds more cash than debt, a net cash position of 184.23M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 5 analysts cover the stock; their mean price target of 37.00 USD is 29.0% above the current price. The next earnings report is expected on 18 February 2027.